Characterization of breast cancer is often leveraged to classify patients into disease pathways based on surface receptor expression of Estrogen receptor (ER), Progesterone receptor (PR), and Human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ESR1 and breast carcinoma.